S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
Top-Rated StocksTop-Rated
NASDAQ:NTRA

Natera (NTRA) Stock Forecast, Price & News

$43.95
+0.27 (+0.62%)
(As of 10/3/2023 ET)
Compare
Today's Range
$43.02
▼
$43.99
50-Day Range
$43.40
▼
$62.52
52-Week Range
$34.00
▼
$63.00
Volume
1.37 million shs
Average Volume
1.33 million shs
Market Capitalization
$5.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Natera MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
54.7% Upside
$68.00 Price Target
Short Interest
Bearish
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Natera in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$1.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.03) to ($2.64) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

349th out of 966 stocks

Medical Laboratories Industry

10th out of 24 stocks

See Top Rated MarketRank™ Stocks Here

NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Price History

NTRA Stock News Headlines

October 2, 2023 | finance.yahoo.com
Natera Submits First PMA Module to the FDA for Signatera™
October 2, 2023 | americanbankingnews.com
Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells $33,540.24 in Stock
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
October 2, 2023 | americanbankingnews.com
Natera, Inc. (NASDAQ:NTRA) CFO Sells $63,084.56 in Stock
October 1, 2023 | americanbankingnews.com
Natera, Inc. (NASDAQ:NTRA) CEO Sells $119,910.94 in Stock
September 30, 2023 | finance.yahoo.com
Insider Sell: CFO Michael Brophy Sells 2,291 Shares of Natera Inc
September 30, 2023 | americanbankingnews.com
Natera (NASDAQ:NTRA) Now Covered by Analysts at Sanford C. Bernstein
September 29, 2023 | msn.com
Bernstein Initiates Coverage of Natera (NTRA) with Market Perform Recommendation
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 18, 2023 | finance.yahoo.com
Natera Announces Senior Leadership Appointments
September 14, 2023 | finance.yahoo.com
Unveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive Guide
September 14, 2023 | finance.yahoo.com
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
September 7, 2023 | msn.com
Natera down 3%, prices $250M follow-on offering
September 7, 2023 | markets.businessinsider.com
Natera Prices Follow-On Offering At $55/share, Totaling $250 Mln
September 7, 2023 | finance.yahoo.com
Natera Announces Pricing of $250 Million Follow-On Offering
September 6, 2023 | barrons.com
Natera Inc.
September 5, 2023 | finance.yahoo.com
Natera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price Decline
September 2, 2023 | uk.finance.yahoo.com
Natera, Inc. (NTRA) stock price, news, quote & history – Yahoo Finance
August 23, 2023 | fool.com
Natera (NASDAQ: NTRA)
August 16, 2023 | finance.yahoo.com
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
August 15, 2023 | seekingalpha.com
Natera: Strong Growth Amidst Profitability Challenges
August 8, 2023 | msn.com
Morgan Stanley Maintains Natera (NTRA) Overweight Recommendation
August 8, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Natera
August 5, 2023 | finance.yahoo.com
Natera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Call Transcript
August 4, 2023 | seekingalpha.com
Natera, Inc. 2023 Q2 - Results - Earnings Call Presentation
August 3, 2023 | finance.yahoo.com
Natera Reports Second Quarter 2023 Financial Results
August 3, 2023 | finance.yahoo.com
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
8/03/2023
Today
10/04/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
CUSIP
N/A
CIK
1604821
Web
www.natera.com
Phone
(650) 249-9090
Fax
N/A
Employees
3,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$68.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+54.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-547,800,000.00
Net Margins
-54.97%
Pretax Margin
-54.92%
Return on Equity
-88.47%
Return on Assets
-41.19%

Debt

Debt-to-Equity Ratio
0.47
Current Ratio
3.85
Quick Ratio
3.69

Sales & Book Value

Annual Sales
$820.22 million
Price / Sales
6.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.23 per share
Price / Book
6.08

Miscellaneous

Outstanding Shares
114,600,000
Free Float
103,806,000
Market Cap
$5.04 billion
Optionable
Optionable
Beta
1.17
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Matthew Rabinowitz Ph.D. (Age 50)
    Co-Founder & Exec. Chairman
    Comp: $441.58k
  • Mr. Steven Leonard ChapmanMr. Steven Leonard Chapman (Age 44)
    CEO & Director
    Comp: $1.15M
  • Mr. Michael B. Brophy M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $611.35k
  • Mr. Daniel Rabinowitz L.L.M.Mr. Daniel Rabinowitz L.L.M. (Age 54)
    LL.M., Sec. & Chief Legal Officer
    Comp: $566.03k
  • Mr. John Fesko
    Pres & Chief Bus. Officer
  • Mr. Jonathan Sheena M.Eng.Mr. Jonathan Sheena M.Eng. (Age 50)
    Co-Founder & Director
  • Ms. Olesya A. Anisimova CPA
    Chief Accounting Officer
  • Mr. Rishi Kacker
    Chief Technology Officer
  • Mr. Eric A. Evans
    Chief Scientific Officer
  • Mr. Jerry Diffley
    Chief Compliance & Privacy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.

What is Natera's stock price forecast for 2023?

7 brokerages have issued 12 month price targets for Natera's shares. Their NTRA share price forecasts range from $48.00 to $80.00. On average, they predict the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2023?

Natera's stock was trading at $40.17 on January 1st, 2023. Since then, NTRA shares have increased by 9.4% and is now trading at $43.95.
View the best growth stocks for 2023 here.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NTRA earnings forecast.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12. The medical research company earned $261.40 million during the quarter, compared to the consensus estimate of $241.67 million. Natera had a negative net margin of 54.97% and a negative trailing twelve-month return on equity of 88.47%. Natera's revenue was up 31.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.50) earnings per share.

What ETFs hold Natera's stock?

ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH).

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $43.95.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $5.04 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($4.82) on an earnings per share basis.

How many employees does Natera have?

The company employs 3,018 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -